馬賽替尼
馬賽替尼是一種**蛋白質酪氨酸激酶抑制劑**，在獸醫學中主要用於治療犬隻無法切除的肥大細胞瘤，特別是確認帶有突變型 c-KIT 受體的病例。目前也正在研究其用於其他發炎和腫瘤疾病的潛力，如異位性皮膚炎、炎症性腸病、骨肉瘤和血管肉瘤。 > **臨床警告：** 馬賽替尼是一種**細胞毒性藥物**。獸醫人員和寵物主人必須嚴格遵守安全和處理規程，以防止意外接觸。
作用機制: Masitinib acts as a **protein tyrosine kinase (TK) inhibitor**. It selectively and effectively binds with high affinity to mutated forms of the **c-KIT tyrosine kinase receptor**. **c-KIT receptor** → Inhibition blocks the TK receptor pathways that are essential for cell replication, survival, and differentiation, thereby halting tumor growth and progression.
各物種劑量
- Non-resectable mast cell tumours (Patnaik grade 2 or 3) · See Appendix for chemotherapy protocols · PO · unknown · unknown · Preferably with a confirmed mutated c-KIT tyrosine kinase receptor.
- Injection site sarcoma, asthma (investigational) · Limited evidence: administered to healthy cats · PO · unknown · unknown · Not licensed in cats. Further clinical trials required. Monitor closely.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新藥品仿單及個別病患確認。
給藥途徑
禁忌症
- Pregnant or lactating bitches
- Dogs < 24 months old
- Dogs < 7 kg body weight
- Pre-existing signs of myelosuppression
- Previous hypersensitivity to masitinib
不良反應
- Diarrhoea (mild to moderate)
- Vomiting (mild to moderate)
- Hair coat changes or alopecia
- Renal toxicity
- Anaemia
- Protein loss (protein-losing nephropathy/enteropathy)
- Myelosuppression
- Increased liver enzyme activity
- Lethargy
- Cough
- Lymphadenomegaly
藥物相互作用
- Highly protein-bound drugs · May displace masitinib or be displaced, increasing the risk of adverse side effects · moderate
- Cytochrome P450 inhibitors or inducers · May alter the metabolism of masitinib, increasing the risk of toxicity or reducing efficacy · moderate
監測
- Blood pressure (baseline and monthly)
- Urinalysis (baseline and monthly)
- Haematology (baseline and monthly)
- Biochemistry (baseline and monthly)
- Coagulation profiles (if adverse signs witnessed)
- Faecal occult blood tests (if adverse signs witnessed)
- Weekly owner check-ins for the first 6 weeks to monitor for side effects
過量
No specific overdose information is provided in the monograph. > **Clinical Pearl:** Overdose of tyrosine kinase inhibitors typically exacerbates gastrointestinal toxicity (severe vomiting, diarrhea) and myelosuppression. Treatment is symptomatic and supportive. Monitor renal and hepatic parameters closely.
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用,不能取代專業判斷或廠方最新藥品說明書。